company background image
TEVA logo

Teva Pharmaceutical Industries TASE:TEVA Stock Report

Last Price

₪59.47

Market Cap

₪65.4b

7D

-1.0%

1Y

25.4%

Updated

16 Feb, 2025

Data

Company Financials +

Teva Pharmaceutical Industries Limited

TASE:TEVA Stock Report

Market Cap: ₪65.4b

TEVA Stock Overview

Develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. More details

TEVA fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Rewards

Trading at 76.1% below our estimate of its fair value

Earnings are forecast to grow 67.72% per year

Trading at good value compared to peers and industry

Risk Analysis

Volatile share price over the past 3 months compared to the IL market

Significant insider selling over the past 3 months


My Notes

Capture your thoughts, links and company narrative

Teva Pharmaceutical Industries Limited Competitors

InterCure

TASE:INCR

₪269.8m

Rekah Pharmaceutical Industry

TASE:REKA

₪168.1m

Royalty Pharma

NasdaqGS:RPRX

US$18.7b

Bayer

XTRA:BAYN

€21.0b

Price History & Performance

Summary of share price highs, lows and changes for Teva Pharmaceutical Industries
Historical stock prices
Current Share PriceUS$59.47
52 Week HighUS$84.31
52 Week LowUS$46.71
Beta0.71
1 Month Change-24.16%
3 Month Change-2.22%
1 Year Change25.41%
3 Year Change126.29%
5 Year Change34.21%
Change since IPO545.72%

Recent News & Updates

Recent updates

Shareholder Returns

TEVAIL PharmaceuticalsIL Market
7D-1.0%-0.2%0.05%
1Y25.4%-15.1%33.0%

Return vs Industry: TEVA exceeded the IL Pharmaceuticals industry which returned -12.8% over the past year.

Return vs Market: TEVA underperformed the IL Market which returned 34% over the past year.

Price Volatility

Is TEVA's price volatile compared to industry and market?
TEVA volatility
TEVA Average Weekly Movement8.3%
Pharmaceuticals Industry Average Movement5.3%
Market Average Movement4.5%
10% most volatile stocks in IL Market9.0%
10% least volatile stocks in IL Market3.0%

Stable Share Price: TEVA's share price has been volatile over the past 3 months compared to the IL market.

Volatility Over Time: TEVA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of IL stocks.

About the Company

FoundedEmployeesCEOWebsite
190134,789Richard Franciswww.tevapharm.com

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas.

Teva Pharmaceutical Industries Limited Fundamentals Summary

How do Teva Pharmaceutical Industries's earnings and revenue compare to its market cap?
TEVA fundamental statistics
Market cap₪65.38b
Earnings (TTM)-₪5.82b
Revenue (TTM)₪58.71b

1.1x

P/S Ratio

-11.2x

P/E Ratio

Is TEVA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TEVA income statement (TTM)
RevenueUS$16.54b
Cost of RevenueUS$8.48b
Gross ProfitUS$8.06b
Other ExpensesUS$9.70b
Earnings-US$1.64b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.45
Gross Margin48.74%
Net Profit Margin-9.91%
Debt/Equity Ratio310.9%

How did TEVA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/16 09:46
End of Day Share Price 2025/02/13 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Teva Pharmaceutical Industries Limited is covered by 59 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Balaji PrasadBarclays
Balaji PrasadBarclays